Published Feb 28, 2026 | 4:41 PM ⚊ Updated Feb 28, 2026 | 4:41 PM
Kerala was among the first states in India to provide free SMA treatment in 2022. Credit: iStock
Synopsis: Kerala has expanded its KARE scheme to provide free Risdiplam treatment for Spinal Muscular Atrophy (SMA) Type 2 patients up to 25 years, marking a first in India. Announced on Rare Disease Day 2026, the move benefits nearly 80% of confirmed SMA patients, backed by a ₹30 crore budget allocation.
On Rare Disease Day 2026, Kerala’s Health Department announced a landmark expansion of its KARE (Keraal Against Rare Diseases) scheme, extending free Risdiplam treatment to Spinal Muscular Atrophy (SMA) Type 2 patients up to 25 years of age.
Previously restricted to children under 12, the move — the first of its kind in India — is expected to benefit nearly 80% of genetically confirmed SMA patients in Kerala.
Health Minister Veena George said the decision follows sustained advocacy by patients and support groups. The state has earmarked ₹30 crore in the latest Budget to fund the expansion.
Under KARE, medicines are distributed based on genetic testing and recommendations from an expert medical committee, ensuring equitable access. Officials note that more than 100 children are already receiving government-supported treatment, showing visible improvements in growth and mobility.
SMA, a rare genetic neuromuscular disorder, causes progressive muscle weakness and can lead to severe disability or early mortality. Free access to Risdiplam is expected to significantly improve quality of life, functional independence, and long-term survival among young patients.
Kerala was among the first states in India to provide free SMA treatment in 2022. This expansion strengthens its rare disease care framework and reflects the Rare Disease Day 2026 theme, “More than you can imagine,” highlighting hidden struggles faced by patients and families.
